JP Morgan Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $30

Benzinga · 10/08 17:57
JP Morgan analyst Jessica Fye initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $30.